Endonovo Therapeutics (ENDV) Stock Chart & Stock Price History $0.0001 0.00 (-50.00%) As of 08/22/2025 11:13 AM Eastern Add Compare Share Share Chart Stock AnalysisChartSEC FilingsShort InterestBuy This Stock Endonovo Therapeutics Stock Price Performance The Endonovo Therapeutics (ENDV) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 93.33%, with a year-to-date return of -75.00%. In the past month, the stock has decreased 50.00%, reflecting recent market activity. As of the latest close, Endonovo Therapeutics traded at $0.00 with a market cap of $121 thousand and volume of 183.40 million shares. Five years ago, the stock traded at $0.11, representing a 99.91% decrease over that period. At the time, it had a market cap of $105.27 million and a volume of 34,422 shares. Receive ENDV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance0.00%1 Month Performance-50.00%Year-To-Date Performance-75.00%1 Year Performance-93.33%5 Year Performance-99.91% ENDV Stock Chart for Monday, August, 25, 2025 ENDV Chart by TradingView Endonovo Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/22/2025$0.00$0.00$0.00$0.00183.40 million shs$121,000.0008/21/2025$0.00$0.00$0.00$0.00100,000 shs$121,000.0008/20/2025$0.00$0.00-50.00%$0.00$0.00130,010 shs$121,000.0008/19/2025$0.00$0.00$0.00$0.00250,000 shs$241,000.0008/18/2025$0.00$0.00$0.00$0.00250,000 shs$241,000.0008/15/2025$0.00$0.00$0.00$0.00100 shs$241,000.0008/14/2025$0.00$0.00$0.00$0.00585,050 shs$241,000.0008/13/2025$0.00$0.00$0.00$0.001.35 million shs$241,000.0008/12/2025$0.00$0.00$0.00$0.00601,500 shs$241,000.0008/11/2025$0.00$0.00+100.00%$0.00$0.0026.20 million shs$241,000.00 Get the Latest News and Ratings for ENDV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/08/2025$0.00$0.00$0.00$0.00100.50 million shs$121,000.0008/07/2025$0.00$0.00$0.00$0.002.31 million shs$121,000.0008/06/2025$0.00$0.00$0.00$0.002,050 shs$121,000.0008/05/2025$0.00$0.00$0.00$0.006.47 million shs$121,000.0008/04/2025$0.00$0.00-50.00%$0.00$0.006,002 shs$121,000.0008/01/2025$0.00$0.00$0.00$0.00109,000 shs$241,000.0007/31/2025$0.00$0.00$0.00$0.00109,000 shs$241,000.0007/30/2025$0.00$0.00$0.00$0.00328,164 shs$241,000.0007/29/2025$0.00$0.00$0.00$0.00606,044 shs$241,000.0007/28/2025$0.00$0.00$0.00$0.005.13 million shs$241,000.0007/25/2025$0.00$0.00+100.00%$0.00$0.0040.40 million shs$241,000.0007/24/2025$0.00$0.00$0.00$0.0047.90 million shs$121,000.00 Related Companies UMGP Stock Chart ARTH Stock Chart NIMU Stock Chart BIOL Stock Chart NUWE Stock Chart TTOO Stock Chart IONM Stock Chart HSDT Stock Chart INLB Stock Chart SDCCQ Stock Chart Receive ENDV Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:ENDV) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endonovo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endonovo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access